Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.01) earnings per share for the quarter, Zacks reports. The company had revenue of $0.08 million during the quarter.
Appili Therapeutics Stock Down 1.4%
APLIF opened at $0.01 on Friday. Appili Therapeutics has a 52-week low of $0.01 and a 52-week high of $0.03. The company has a market cap of $1.82 million, a P/E ratio of -0.47 and a beta of -0.28. The firm’s 50-day moving average price is $0.02 and its 200-day moving average price is $0.02.
About Appili Therapeutics
Appili Therapeutics Inc is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada. The company specializes in the development and commercialization of novel anti-infective therapies designed to address both endemic and emerging infectious disease threats. Appili’s strategic focus includes small-molecule antibiotics, antivirals and vaccine adjuvants, with an emphasis on formulations suitable for rapid deployment in resource-limited or outbreak settings.
Appili’s product pipeline features multiple candidates in various stages of development.
Further Reading
- Five stocks we like better than Appili Therapeutics
- ALERT: Drop these 5 stocks before January 2026!
- Think You Missed Silver? You’re Wrong. Here’s Why.
- Trump’s AI Secret: 100X Faster Than Nvidia
- Your Bank Account Is No Longer Safe
- The Next Commodity Crunch (bigger than oil?)
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
